Last reviewed · How we verify
NCT04345393
Translating Scientific Evidence Into Practice Using Digital Medicine and Electronic Patient Reported Outcomes
NA trial testing Digital Transformation Network (DTN) Program in Inflammatory Bowel Disease (IBD) in 543 participants. Completed in 24 March 2025.
24 March 2025
Quick facts
| Lead sponsor | Icahn School of Medicine at Mount Sinai |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 543 |
| Start date | 14 May 2022 |
| Primary completion | 24 March 2025 |
| Estimated completion | 24 March 2025 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- Digital Transformation Network (DTN) Program
Conditions studied
- Inflammatory Bowel Disease (IBD) — all drugs for Inflammatory Bowel Disease (IBD) →
Sponsor
Icahn School of Medicine at Mount Sinai
Who can join
18 and older, any sex, with Inflammatory Bowel Disease (IBD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Delivery of healthcare has been traditionally limited to in-person visits or hospitalizations, while patients spend the majority of their time at home or work. Digital Medicine (e.g. apps, remote monitoring, telemedicine, patient reported outcomes) has the potential to bridge this gap, but the question remains as to how to translate it to mainstream practice while providing individualized recommendations to improve population health across organizations. Through the creation of a Digital Transformation Network (DTN) for Inflammatory Bowel Disease (IBD), the study team plans to reduce digital disparities and scientifically test the impact of these technologies in a clinical trial in three CTSA sites catering to diverse populations and communities.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Psychological interventions for treatment of inflammatory bowel disease.
Tiles-Sar N, Neuser J, de Sordi D, Baltes A, et al · · 2025 · cited 5× · PMID 40243391 · DOI 10.1002/14651858.cd006913.pub3
Verify or expand the search:
- PubMed search for NCT04345393
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Inflammatory Bowel Disease (IBD)
Currently open trials in the same condition.
- NCT07245394 — Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD) · recruiting
- NCT07237516 — Zymfentra (Infliximab-dyyb) REal World Cohort STudy · recruiting
- NCT07224113 — Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD · recruiting
- NCT07221890 — A Trial of Academic Detailing to Promote Prescribing of Biosimilars · NA · active not recruiting
- NCT07355101 — Personalized Exercise Coaching to Improve Quality of Life in Pediatric IBD · NA · active not recruiting
Other Icahn School of Medicine at Mount Sinai trials
Trials by the same sponsor.
- NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
- NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
- NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
- NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
- NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04345393 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
- Last refreshed: 30 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04345393.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing